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Aims: To assess the value of a near-patient brain natriuretic peptide (BNP) test to predict medium term
(3 month) serious outcome for adult syncope patients presenting to a UK emergency department (ED).
Methods: This was a prospective cohort pilot study. Consecutive patients aged >16 years presenting with
syncope over a 3 month period were eligible for prospective enrolment. All patients who were medium or
high risk according to our ED’s existing syncope guidelines underwent near-patient BNP testing using the
Triage point of care machine.
Results: 99 patients were recruited. 72 of 82 high and medium risk patients underwent BNP measurement. 11
patients had a serious outcome, 9 of whom had BNP measured. In 25 (35%) patients, BNP was>100 pg/ml,
and in 3 of these it was.1000 pg/ml. 6 of the 25 patients (24%) with a BNP.100 pg/ml, and all 3 patients
with a BNP .1000 pg/ml, were in the serious outcome group. BNP was raised over 100 pg/ml in 6 of the 9
serious outcome patients having a BNP measured (66%), and over 1000 pg/ml in 3 (33%).
Conclusions: This early work suggests that BNP may have a role in the risk assessment of syncope patients in
the ED. Further work is required to see how BNP interacts with other clinical variables. Near-patient BNP
testing may be shown to be an independent predictor of adverse outcome either alone or incorporated into
existing syncope clinical decision rules and scores in order to improve their sensitivity and specificity. Further
studies are required to evaluate this.
S
yncope is a transient, self limited loss of consciousness
usually leading to falling.1 It accounts for 3% of emergency
department (ED) visits and 1–6% of hospital medical
admissions, affecting 6 per 1000 people per year.2 3 In 1983,
Kapoor et al4 published the first prospective syncope study
showing a 12 month mortality of 14%. Mortality was greatest in
patients in whom a cardiovascular cause was identified (30%).
Subsequent studies have shown that underlying heart disease
in patients with syncope is associated with a poor prognosis.5
Recent emphasis has focused on risk stratifying syncope
patients. With growing pressures on acute medical beds and an
increasingly elderly population, there is a need to identify high
risk populations requiring further investigation, and low risk
patients who may be discharged safely. Accurate identification
of such groups would enable specific targeting of resources and
prevent excessive investigation of patients with benign causes
of syncope. No risk stratification studies have yet investigated
the role of biochemical markers in risk stratification.
Brain (or B-type) natriuretic peptide (BNP), which is secreted
in response to an increase in ventricular volume and pressure
load, is known to be an excellent marker of prognosis in
patients with heart failure or cardiac disease.6 7 As previously
mentioned, it is well established that prognosis in syncope is
related to the presence of underlying heart disease,5 and all
existing syncope clinical decision rules include either a history
of congestive heart failure8–11 or of underlying cardiac dis-
ease.12 13 Tanimoto et al in 2004 conducted the only syncope
study to date that has utilised BNP.14 This study evaluated the
usefulness of BNP to separate cardiac and non-cardiac causes of
syncope. The investigators retrospectively evaluated 148 con-
secutive syncope patients admitted to hospital; 61 of these
patients were found to have a cardiac cause for their syncope. A
BNP value of>40 pg/ml was found to be 82% sensitive and 92%
specific for identifying cardiac syncope.
We therefore hypothesised that BNP could be an excellent ED
marker of medium term (3 month) syncope outcome. The aim
of this pilot study was to assess the value of a near-patient BNP
test to predict medium term (3 month) serious outcome for
syncope patients presenting to a UK ED, and to compare the
performance of BNP with our existing departmental syncope
guidelines (table 1) based on the European Society of
Cardiology,1 15 the American College of Physicians,16 17 and the
American College of Emergency Physicians guidelines.18
METHODS
Setting
The ED of the Royal Infirmary of Edinburgh (85 000 adult
attendances per annum).
Inclusion criteria
Consecutive patients presenting with syncope aged 16 years or
over between 7 November 2005 and 7 February 2006 were
eligible for prospective enrolment. Syncope was defined as a
transient loss of consciousness with an inability to maintain
postural tone, followed by a spontaneous recovery without need
for therapeutic or electrical intervention. Data from this same
patient cohort were used to compare our existing ED guidelines
with the San Francisco Syncope Rule10 11 and the OESIL score,13
and has been published previously.19
Exclusion criteria
Patients under 16 years of age, those previously recruited, and
those having a history of seizure with prolonged post-ictal
phase were excluded. Patients who were unable to give either
written or verbal informed consent were also excluded.
Abbreviations: BNP, brain natriuretic peptide; CT, computed tomography;
ECG, electrocardiogram; ED, emergency department; EPR, electronic
patient records; IQR, interquartile range
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Study enrolment
Eligible patients were flagged at the ED high dependency triage
area and a data collection form was placed in the patient’s
records. The treating doctor was responsible for deciding
eligibility. Assessment of patients was carried out by routine
ED clinical staff. A decision to enrol a patient was not
overturned later by the study team and enrolled patients were
analysed on an intention to treat basis. Written consent was
obtained from all enrolled patients. This study received ethical
approval from Lothian’s Regional Ethical Committee.
Assessment
All patients underwent a standardised assessment using 31 pre-
determined variables (11 focused on clinical features, 9 on past
medical history, and 11 concerning current medication), 28
examination variables and 26 electrocardiogram (ECG) vari-
ables. After a full history and examination, all patients who
were medium or high risk according to our ED’s existing
syncope guidelines also had near-patient BNP testing. BNP was
measured using a whole blood immunoassay technique
utilising the Triage point of care machine. Treating physicians
were not blinded to the result of the BNP test. Admitted
patients also underwent a laboratory based troponin I at least 12 h
post-syncope at the discretion of the admitting team. Patients
were admitted, referred to medical outpatients, or discharged
according to our ED’s existing syncope guidelines and a study data
collection form was completed for each patient.
End point measures
The primary end point was serious outcome at 3 months.
Serious outcomes were pre-defined and were all cause death,
acute myocardial infarction (history of chest pain or ECG
changes and troponin I .2.0), life threatening arrhythmia
(documented on monitor or ECG during inpatient stay or on
outpatient Holter monitoring, and requiring treatment), pul-
monary embolus (confirmed on ventilation perfusion scan (VQ)
or CT pulmonary angiography scan (CTPA), and requiring
treatment), cerebrovascular accident/subarachnoid haemor-
rhage (CT or lumbar puncture diagnosis), haemorrhage
requiring a blood transfusion of 2 units or more during
inpatient stay, and an acute surgical procedure or endoscopic
intervention secondary to a suspected cause of syncope.
Once 3 months had elapsed following ED attendance, the
hospital computer system was interrogated to see whether each
patient had returned to any hospital in the Lothian region. The
hospital records were reviewed for all patients who had
attended the ED or outpatient department or who had been
admitted as an inpatient. Any deceased patient in the Lothian
region was also able to be identified via the hospital computer
system and hospital records were acquired.
Hospital notes were reviewed to determine whether each
patient had had a serious outcome within 3 months of their
attendance to the ED with syncope. All patients were followed
up. Two recruited patients from outside Lothian were contacted
by phone. Hospital notes were available for all patients.
Table 1 Our existing emergency department syncope guidelines based on the European
Society of Cardiology,1 15 the American College of Physicians,16 17 and the American College of
Emergency Physicians guidelines18
High risk (admit) Medium risk (consider discharge with early outpatient review)
History findings History findings
l Palpitations related to syncope l Age .60 years
l Associated chest pain l No prodromal symptoms
l Associated headache l Previous myocardial infarct
l Related to exertion l Known history of valvular heart disease
l Family history of sudden death ,60 l Known angina/coronary artery disease
l Previous history of VT/VF/cardiac arrest l Known history of congestive cardiac failure
Examination findings Examination findings
l Systolic heart murmur heard l .20 mm Hg drop on standing
l Signs of heart failure present l Diastolic heart murmur heard
l Systolic BP ,90 mm Hg l Ventricular pause .3 s on carotid sinus massage
l Suspicion of pulmonary embolism l Trauma associated with collapse
l AAA detected
l New neurological signs on examination ECG findings
l Suspicion of CVA or SAH l Right bundle branch block
l FOB present on PR exam l QRS duration .120 ms
l Other suspicions of GI bleed l Old T wave/ST segment changes
l Frequent pre-excited QRS complexes
ECG findings l Q waves unchanged from old ECG
l Mobitz type II second degree heart block l Atrial fibrillation or flutter
l Mobitz type I (aka Wenkebach) second
degree heart block
l PR .200 ms (1st degree heart block)
l Bifascicular block
l Complete heart block Low risk (consider discharge)
l Sinus pause .3 s l None of the above characteristics
l New ST elevation
l VT
l Sinus bradycardia ,50
l Sinoatrial block
l QTc .450 ms
l New T wave/ST segment changes
l Brugada syndrome (ST segment elevation
V1–V3)
l Arrhythmogenic right ventricular dysplasia
AAA, abdominal aortic aneurysm; BP, blood pressure; CVA, cerebrovascular accident; ECG, electrocardiogram; FOB,
faecal occult blood; GI, gastrointestinal; PR, per rectum; SAH, subarachnoid haemorrhage; VF, ventricular fibrillation;
VT, ventricular tachycardia.
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Review of missed patients
In order to determine the recruitment rate of patients into the
study, a retrospective search was conducted of all ED electronic
patient records (EPR) between 7 November 2005 and 7
February 2006 looking for the keywords ‘‘syncope’’, ‘‘collapse’’,
‘‘faint’’, ‘‘loss of consciousness’’ or ‘‘loc’’ appearing anywhere
on the EPR. All EPRs with one of these terms were then hand
searched and a decision was made from the notes whether the
patient fitted the study’s inclusion criteria. A list was compiled
of all patients who fitted the study inclusion criteria but who
had not been enrolled, along with their demographic details,
and these were compared to those patients who had been
enrolled into the study.
Statistical analysis
All patient data were entered into a specially designed
Microsoft Access database and exported into Microsoft Excel
for statistical analysis. Sensitivity, specificity, predictive values
and likelihood ratios were calculated for BNP .100 pg/ml, BNP
.1000 pg/ml and for current ED guidelines, and serious and
non-serious outcome groups were compared using the Fisher
exact test. The small sample size precluded calculation of
receiver operator curves. The BNP cut off values of 100 pg/ml
and 1000 pg/ml were decided before the study. The Triage point
of care BNP assay defines any BNP value .100 pg/ml as an
abnormal value. This value and a value 10-fold greater were
arbitrarily chosen for analysis. This upper cut off was chosen as it
was thought to be potentially high enough to be a possible rule-in
value. A future larger study will attempt to define possible rule-in
and rule-out levels using receiver operator curves.
The ‘‘study group’’ and the ‘‘missed group’’ were compared
using the x2 test and the Mann–Whitney U test, and the ‘‘BNP
group’’ and the ‘‘missed BNP’’ group were compared using the
Fisher exact test.
RESULTS
Ninety-nine consecutive adult patients were recruited over a
3 month period between 7 November 2005 and 7 February
2006. It was thought that 100 patients had been enrolled;
however, one patient episode had been erroneously duplicated
Table 2 Description of the 11 patients with a serious outcome
Patient
study no. Age Sex Serious outcome Patient ESC risk
BNP
pg/ml
7 68 M Extreme bradycardia on 24 h tape including 2 pauses of 3.5 s and 4.0 s. Permanent
pacemaker inserted. Alive at 3 months
Medium 461
17 71 M Had AAA repair on day 1 with good recovery. Presented to the ED day 80 with leaking
AAA repair. Died in theatre
High –
24 90 F Myocardial infarction (troponin 14.40). Also fast AF. Alive at 3 months High 1340
32 67 M Re-presented to the emergency department in cardiac arrest day 32. Unsuccessfully
resuscitated. Primary cause unknown
High 2040
43 91 M Ventricular standstill on ward. Permanent pacemaker inserted. Alive at 3 months High 82.5
52 66 M Died in hospital on day 79 after a hospital readmission. Cause not identified High 26.5
55 76 M Multiple episodes of ventricular tachycardia on ward. Internal defibrillator implanted.
Alive at 3 months
High –
59 76 M 2 episodes of ventricular standstill 7 s and 5 s each on 24 h tape. Diagnosis of episodic
complete heart block made and permanent pacemaker inserted. Alive at 3 months
Medium 16.3
63 57 F Died day 6 after index hospital admission. Syncope secondary to massive upper
gastrointestinal haemorrhage. Patient also had terminal lung cancer
High 1040
66 74 M Died day 6 after index hospital admission of left internal carotid artery thrombosis and
left cerebral infarct. Also secondary right sided bronchopneumonia
Medium 144
78 81 F Initial syncope thought secondary to hypotension. Interval 24 h tape showed episodes of fast
AF and 5 prolonged pauses up to 3.6 s. Permanent pacemaker inserted. Alive at 3 months
Medium 489
AAA, abdominal aortic aneurysm; AF, atrial fibrillation; BNP, brain natriuretic peptide; ED, emergency department; ESC, European Society of Cardiology; F, female;
M, male.
Table 3 Summary of results
Serious outcome No serious outcome Total
Total patients 11 (11%) 88 (89%) 99
Admitted 11 (25%) 33 (75%) 44
Discharged 0 (0%) 55 (100%) 55
High risk group (based on ED guidelines) 7 (22%) 25 (78%) 32
Medium risk group (based on ED guidelines) 4 (8%) 47 (92%) 51
Low risk group (based on ED guidelines) 0 (0%) 16 (100%) 16
BNP not measured 2 (7%) 25 (93%) 27
BNP ,100 pg/ml 3 (6%) 44 (94%) 47
BNP >100 pg/ml but ,1000 pg/ml 3 (14%) 19 (86%) 22
BNP >1000 pg/ml 3 (100%) 0 (0%) 3
BNP, brain natriuretic peptide; ED, emergency department.
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during data entry. Forty-four patients were admitted to hospital
and 55 were discharged from the ED. Eight of the 11 patients
with a serious outcome had this by 7 days, and three further
patients had developed a serious outcome by 3 months. In total,
therefore, 11 patients (11.1%) had a serious outcome by
3 months. Of these, five patients had died and six others had
an alternative serious outcome (table 2). All 11 had been
admitted to hospital from the ED (table 3).
Seventy-two of the 82 medium and high risk patients had
BNP measured, nine of whom had a serious outcome (12.5%)
(fig 1). Those medium and high risk patients who did not
undergo BNP measurement were missed because of either
enrolling doctor error (seven patients) or BNP Triage point of
care machine or operator error (three patients). The percentage
serious outcome in those high and medium risk patients having
BNP measured (72 patients) and the percentage serious
outcome in the high and medium risk patients who did have
BNP measured (10 patients) was not significantly different
(p = 0.617, ns, Fisher exact test).
A BNP cut off of>100 pg/ml was more sensitive than current
ED guidelines for predicting medium term (3 month) serious
outcome for syncope patients presenting to our ED (0.667 vs
0.636) with a similar specificity (table 4). A BNP cut off of
>1000 pg/ml had a specificity of 1 compared to that of 0.716 for
current ED guidelines. While the BNP in two of these patients
would have been unlikely to affect a decision to admit (acute
myocardial infarction and massive upper gastrointestinal bleed
both apparent on admission), in the third, there was no
suspicion of likely poor outcome at the time of the patient’s
initial presentation to the ED.
Thirty of those admitted had troponin I measured, and only
one of these was raised (14.40 ng/ml). This was thought to be
due to an acute myocardial infarction. Of the 11 patients who
developed a serious outcome, six had troponin measured and in
only one was it raised.
A total of 263 patients presenting during the study period
were identified from the EPR search as fitting the study’s
inclusion criteria. The study therefore enrolled 37.6% of
patients eligible for inclusion. There were 74 men (45%) and
90 women in the ‘‘missed group’’, compared to 48 men (48%)
and 51 women in the ‘‘study group’’ (p = 0.60, ns, x2). Neither
the ages of the ‘‘study group’’ or ‘‘missed group’’ were normally
distributed. Median age of the ‘‘study group’’ was 71.0 years
(interquartile range (IQR) 47–81 years) and of the ‘‘missed
group’’ was 62.5 years (IQR 29–78 years) (p = 0.047, significant
at the 5% level, Mann–Whitney U test).
Figure 1 Relation between brain natriuretic peptide (BNP) level and
outcome of study patients at 3 months.
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DISCUSSION
This is the first study that has looked at using biochemical
markers to aid rapid risk stratification of patients presenting to
the ED with syncope. There are currently several risk
stratification scores8–13 and also various guidelines to help the
emergency physician decide who should be admitted for further
investigation, and who could be safely discharged. Some of
these rules have been derived to predict short term outcome
(7 days) and some to predict longer term outcome
(12 months).
We chose to look at a medium term (3 month) serious
outcome. The goal of an ED risk stratification tool is to detect
patients who are at risk of an imminent serious outcome, the
course of which may be altered by early investigation,
admission and intervention. A proportion of the short term
(7 day) serious outcomes were expected to include such
conditions as ruptured abdominal aortic aneurysms and
subarachnoid haemorrhages. BNP is unlikely to be useful at
predicting serious outcome in this non-cardiac syncope group.
We also decided not to measure BNP in patients who were
classified as low risk. This was because of the expected very low
rate of serious outcome in this group.
Only one patient who had an adverse outcome had a raised
troponin I at 12 h. This suggests that the good sensitivity that
BNP shows for serious outcome is not due to it acting as a
marker of myocardial ischaemia.
Patients who had been ‘‘missed’’ for inclusion into the study
were statistically slightly younger compared to those enrolled into
the ‘‘study’’ group. This is probably due to ED staff failing to enrol
some younger syncope patients into the study. These patients
would be more likely to be low risk and would therefore not have
been eligible for BNP and troponin I testing. This difference is
therefore unlikely to have biased the study findings.
This study shows that BNP may be a very useful predictor of
serious outcome in syncope patients presenting to the ED. The
advantage of the near-patient test is its immediate availability
which makes it extremely useful for rapid ED decision making.
BNP should now be included as a predictor variable in a large
derivation and validation study of syncope to see if it is an
independent predictor of adverse outcome and, if so, whether it
has a role alone or as part of a clinical decision rule to aid the
management of patients presenting with possible cardiac
syncope to the ED. A power calculation suggests that 500
patients would be required in both the derivation and
validation arms of such a study.
Conclusions
This early work suggests that BNP may have a role in the risk
assessment of syncope patients in the ED. Further work is
required to see how BNP interacts with other clinical variables.
A BNP cut off of >100 pg/ml has a reasonable sensitivity for
serious outcome, while a cut off of >1000 pg/ml has an
excellent positive predictive value and specificity. Near-patient
BNP testing may be shown to be an independent predictor of
adverse outcome either alone or incorporated into existing
syncope clinical decision rules and scores in order to improve
their sensitivity and specificity. Further studies are required to
evaluate this.
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